CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Ubiquinol +1 moredrug
Likely dose
Ubiquinol 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03061513
NCT03061513Phase 2Completed
CompareCT.gov

Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

Weill Medical College of Cornell University·interventional·Posted Feb 23, 2017·Updated May 23, 2017

In Brief

A Phase 2 clinical trial evaluating Ubiquinol and Placebo for Parkinson Disease. Completed, enrolled 11 participants.

Detailed Summary

The purpose of this study is to find out whether ubiquinol is well tolerated, can affect the symptoms of Parkinson's Disease and change the energy levels in the brain. Subjects will be randomized to taking ubiquinol or placebo and will have a neurological evaluation, magnetic resonance spectroscopy (MRS) and blood test for biological markers taken during the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 23, 2017
Enrollment StartFeb 28, 2012
Primary CompletionDec 31, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.4 years ago

Interventions

Ubiquinoldrug

Ubiquinol caplets 600mg/day

Placebodietary

placebo